alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 5,051–5,075 of 17,283 studies scoring 30–49 out of 100 (page 203 of 692) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Sex-specific effects of apolipoprotein E ε4 genotype on longitudinal hippocampal atrophy in amnestic mild cognitive impairment over a 2-year evaluation period

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Alzheimer s Disease 2025-02-01

We identified that the APOE4 genotype affected ΔHV in females. 5 key findings →

Design: longitudinal study Participants: 73 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of graph network properties with Alzheimer's pathological hallmarks early in the disease continuum

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-12-01

We found a positive main effect of CSF Aβ42/40 (p = 0.011) and p-tau181 (p = 0.012) on BC of the Dorsal Attention Network (DAN) (Figure 1). 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Risk of a Dementia Diagnosis in Community-Dwelling Older Adults With Normal MMSE Scores in the United States

✓ Peer-reviewed alzhub usefulness score 44 out of 100. American Journal of Medicine Open 2026-02-25

• Lower MMSE scores—even by a single point—were independently associated with a significantly higher risk of developing ADRD. • Individuals with MMSE scores between 27 and 30 should not be viewed as a uniform group. • Further studies are needed to find ways to prevent ADRD in people who are at risk but do not yet show symptoms. 5 key findings →

Participants: 1,228 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Deep cervical lymphatic-venous anastomosis in dementia: a clinical and mechanistic evaluation

✓ Peer-reviewed alzhub usefulness score 44 out of 100. International Journal of Surgery 2025-12-17

Within one week after dcLVA, 64.3% of patients demonstrated MMSE improvement, with further functional gains observed in continence, emotional regulation, motor coordination, and feeding independence. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Assessment of localized brain regions correlated with MMSE using VBM analysis of structural MRI in a Japanese sample

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neuroimage Reports 2025-04-28

The global aging population has led to a significant rise in dementia and cognitive decline, with Alzheimer's disease as the primary cause. 5 key findings →

Design: cross-sectional Participants: 510 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Benson Complex Figure Test for the Differential Diagnosis of Dementias

✓ Peer-reviewed alzhub usefulness score 44 out of 100. NeuroSci 2026-03-20

The Benson Complex Figure Test (BCFT) is a neuropsychological tool designed to assess visuospatial construction and visual memory with lower complexity than traditional tests. 4 key findings →

Design: cross-sectional Participants: 1,428 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Correlation of White Matter Lesions, Cerebral Blood Flow, and Cognitive Decline in Patients With Alzheimer’s Disease and Vascular Dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Archives of Clinical Neuropsychology 2025-12-26

Compared to controls, the AD/VaD patient group had a significantly higher WML volume (p < .001), reduced global CBF (p < .001), greater brain atrophy, and worse ADAS-Cog scores (p < .001). 5 key findings →

Design: cross-sectional Participants: 100 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The yes-no reversal phenomenon: Prevalence and correlates in mild cognitive impairment and dementia due to neurodegenerative, chronic cerebrovascular, and mixed etiologies

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Alzheimer s Disease 2026-02-09

BackgroundThe yes-no reversal (YNR) phenomenon consists in a patient saying "yes" when meaning "no", or vice-versa. 3 key findings →

Participants: 267 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Associations of adherence to a healthy sleep pattern with the dementia risk in the UK biobank

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s Research & Therapy 2025-09-30

During a median follow-up of 13.8 years, 3,035 incident dementia cases were recorded, including 1,304 Alzheimer's disease (AD) cases and 597 vascular dementia (VD) cases. 5 key findings →

Participants: 33,401 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropsychological phenotypic characteristics in a cohort of community-based older adults: Data from the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Alzheimer s Disease 2025-04-23

BackgroundNeuropsychological (NP) assessment is crucial for diagnosing prodromal and Alzheimer's disease and related dementia (ADRD) syndromes. 3 key findings →

Participants: 1,195 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Heart rate response and recovery during exercise and dementia risk: a prospective UK biobank study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Scientific Reports 2025-11-03

The heart rate response/recovery (HRR) index, a common indicator for cardiovascular health during exercise, has been linked with neurocognitive disorders and mortality. 4 key findings →

Participants: 519 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Perspective: Emerging challenges for a future ADNI

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-02-01

In the last two decades, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has significantly advanced our understanding, technologies, and methods for detecting and diagnosing Alzheimer's disease and related dementias. 1 key finding →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Associations of Cardiovascular‐Kidney‐Metabolic Syndrome with Psychiatric Disorders and Dementia in Midlife and Older adults in the UK Biobank

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-12-01

Among 389,314 participants, CKM stages were distributed as follows: stage 0 (10.0%), stage 1 (8.0%), stage 2 (57.6%), stage 3 (17.9%), and stage 4 (6.5%). 5 key findings →

Participants: 389,314 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The National Dementia Workforce Study: The Plan for Organization Sample Frames and Data Collection

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of the American Geriatrics Society 2025-09-04

The National Dementia Workforce Study was designed to improve our understanding of the individuals and systems who care for people with dementia, but designing and implementing such a study is challenging due to the large number of patient care organizations, clinical and direct care roles, and locations in which care is provided. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Cells 2025-05-08

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) are two neurodegenerative disorders that share common genes and pathomechanisms and are referred to as the ALS-FTD spectrum. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Endogenous TDP-43 mislocalization in a novel knock-in mouse model reveals DNA repair impairment, inflammation, and neuronal senescence

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Acta Neuropathologica Communications 2025-03-08

TDP-43 mislocalization and aggregation are key pathological features of amyotrophic lateral sclerosis (ALS)- and frontotemporal dementia (FTD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Frontotemporal Lobar degeneration with TDP-43 presenting as progressive supranuclear palsy syndrome

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Acta Neuropathologica Communications 2025-07-09

The most common clinical symptoms in FTLD-TDP-PSP were memory loss (100%) followed by parkinsonism (80%), early falls (60%), and behavioral variant FTD (60%). 5 key findings →

Participants: 270 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Molecular Neurodegeneration 2025-01-13

Here, we found that the level of histone deacetylase 7 (HDAC7) was remarkably increased in the astrocytes of AD patients and P301S tau transgenic (PS19) mice. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Human iPSC-derived APOE4/4 Alzheimer´s disease astrocytes exhibit a senescent and pro-inflammatory state that compromises neuronal support

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Neuroinflammation 2025-12-12

Alzheimer´s disease (AD) is dominated by a complex cellular pathology which involves most brain cell types with glial cells increasingly recognized as playing fundamental roles in neurodegeneration. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events